HETEROARYL COMPOUNDS AND THEIR APPLICATION Russian patent published in 2017 - IPC C07D405/14 C07D403/12 C07D401/12 C07D239/48 C07D239/47 C07D405/12 C07D413/12 A61K31/505 A61K31/506 A61K31/519 A61P35/00 

FIELD: medicine, pharmacy.

SUBSTANCE: present invention relates to new compounds selected from the group of compounds shown below, or pharmaceutically acceptable salts thereof, which have properties of kinase activity inhibitor selected from BTK, ErbB1, ErbB2, ErbB3, ErbB4, TEC, ITK, BMX and JAC3, or the said kinase mutant. At that, one or more kinases may be inhibited irreversibly by covalent cysteine (Cys) modification. The compounds may be used for treatment of rheumatoid arthritis, multiple sclerosis, diabetes, B-cell chronic or acute lymphocytic leukemia, hairy cell leukemia, non-Hodgkin's lymphoma, Hodgkin's lymphoma, multiple myeloma, colorectal cancer, pancreatic cancer, bone cancer, metastasis in the bone, osteoporosis, diabetes, irritable bowel syndrome, Crohn's disease, systemic lupus erythematosus or disorders associated with renal carcinoma transplant selected from breast cancer, glioblastoma, lung cancer, head and neck cancer, colorectal cancer, bladder cancer, non-small cell lung cancer, squamous cell carcinoma, salivary gland carcinoma, ovarian carcinoma, colorectal cancer or pancreatic cancer. Compounds are selected from the group of compounds

, , , , , , ,

and compounds (I-382) - (I-393) specified in the invention formula.

EFFECT: invention can be used to treat many diseases.

16 cl, 25 dwg, 20 tbl, 302 ex